Literature DB >> 3678119

Relationship of serum bilirubin levels and hearing impairment in newborn infants.

L S De Vries1, S Lary, A G Whitelaw, L M Dubowitz.   

Abstract

A comparison has been made between 39 infants with a birthweight of 1500 g or less and a bilirubinlevel of 240 mumol/l or above, born between January 1980 and December 1983 and 19 infants with the same criteria, born between January 1984 and December 1985. Eight of the 22 high risk and two of the 17 low risk infants were diagnosed to have sensorineural deafness (SND) during the first period and this was strongly associated with the duration of the hyperbilirubinaemia. During the second period, more active intervention for hyperbilirubinaemia led to an increased number of exchange transfusions and a marked drop in the mean duration of hyperbilirubinaemia (less than 240 mumol/l). None of the very low birth weight (VLBW) infants born in the second period have developed SND. To investigate the independent effect of hyperbilirubinaemia on hearing, six low risk infants with bilirubin levels less than 320 mumol/l were studied by serial auditory brainstem responses (ABR). Impairment of the ABRs was found in four infants, with further deterioration with the persistence of high bilirubin levels in two. Although recovery of hearing thresholds was noted in all infants with impaired ABRs, an absence of wave I was noted in three infants at 6 months of age, which could indicate damage to the auditory nerve-cochlear complex. These findings suggest that hyperbilirubinaemia in itself can have an adverse effect on hearing and that careful management of hyperbilirubinaemia may reduce the incidence of sensorineural deafness.

Entities:  

Mesh:

Year:  1987        PMID: 3678119     DOI: 10.1016/0378-3782(87)90050-8

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  9 in total

1.  Auditory brainstem responses (ABR) in neonates with hyperbilirubinemia.

Authors:  A K Gupta; H Raj; N K Anand
Journal:  Indian J Pediatr       Date:  1990 Sep-Oct       Impact factor: 1.967

2.  Chronic Auditory Toxicity in Late Preterm and Term Infants With Significant Hyperbilirubinemia.

Authors:  Sanjiv B Amin; Satish Saluja; Arvind Saili; Mark Orlando; Hongyue Wang; Nirupama Laroia; Asha Agarwal
Journal:  Pediatrics       Date:  2017-10       Impact factor: 7.124

Review 3.  Multimodality evoked responses in the neurological assessment of the newborn.

Authors:  E Mercuri; K von Siebenthal; H Daniëls; F Guzzetta; P Casaer
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

4.  Visuocortical function in infants with a history of neonatal jaundice.

Authors:  Chuan Hou; Anthony M Norcia; Ashima Madan; William V Good
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-02       Impact factor: 4.799

5.  Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study.

Authors:  Ellen C Caniglia; Kunjal Patel; Yanling Huo; Paige L Williams; Suad Kapetanovic; Kenneth C Rich; Patricia A Sirois; Denise L Jacobson; Sonia Hernandez-Diaz; Miguel A Hernán; George R Seage
Journal:  AIDS       Date:  2016-05-15       Impact factor: 4.177

Review 6.  Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology.

Authors:  R Cristobal; J S Oghalai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-11       Impact factor: 5.747

7.  Hyperbilirubinemia and language delay in premature infants.

Authors:  Sanjiv B Amin; Diane Prinzing; Gary Myers
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

8.  Hearing impairment in premature newborns-Analysis based on the national hearing screening database in Poland.

Authors:  Katarzyna Wroblewska-Seniuk; Grazyna Greczka; Piotr Dabrowski; Joanna Szyfter-Harris; Jan Mazela
Journal:  PLoS One       Date:  2017-09-14       Impact factor: 3.240

9.  Long-term Effects of Indirect Hyperbilirubinemia on Auditory and Neurological Functions in Term Newborns.

Authors:  Gulser Esen Besli; Fazilet Metin; Mehmet Ateş Aksit; Sema Saltik
Journal:  Medeni Med J       Date:  2020-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.